Assembly Biosciences Inc (ASMB) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Assembly Biosciences Inc (ASMB) following the 2026 Q2 hedge fund 13F filings?

As of today, ASMB has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ASMB gained +19.9% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Assembly Biosciences Inc (ASMB)

71 + Investors. Track Smart Money conviction in ASMB. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — ASMB

Based on 71 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added ASMB than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

71 hedge funds hold ASMB right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +97% more funds vs a year ago

fund count last 6Q

+35 new funds entered over the past year (+97% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 60% buying

43 buying29 selling

Last quarter: 43 funds were net buyers (14 opened a brand new position + 29 added to an existing one). Only 29 were sellers (17 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

⚠️

Fewer new buyers each quarter (-7 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 6 → 31 → 21 → 14. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 59% entered in last year

■ 15% conviction (2yr+) ■ 25% medium ■ 59% new

Only 11 funds (15%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💎

Buying through price weakness — shares -1%, value -20%

Value

-20%

-1%

Last quarter: funds added -1% more shares while total portfolio value only changed -20%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

➡️

Steady discovery — ~14 new funds/quarter

5 → 6 → 31 → 21 → 14 new funds/Q

New funds entering each quarter: 6 → 31 → 21 → 14. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🌱

Early stage — 61% of holders entered in last year

■ 6% veterans ■ 34% 1-2yr ■ 61% new

Of 71 current holders: 43 (61%) entered in the past year, only 4 (6%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

📋

Smaller funds dominant — 13% AUM from top-100

13% from top-100 AUM funds

22 of 71 holders rank in the top 100 by AUM, but together hold only 13% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

5.8

out of 10

Moderate Exit Risk

Exit risk score 5.8/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	71	69	2.9%
13F Shares	14M	14M	-1.09%
Total Value	$374M	$467M	-20.07%
New Positions	14	21	-7
Increased Positions	29	24	+5
Closed Positions	12	10	+2
Reduced Positions	17	14	+3
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

2.9%

13F Shares

14M

-1.09%

Total Value

$374M

$467M

-20.07%

New Positions

-7

Increased Positions

Closed Positions

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

71 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ASMB. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 ASMB holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Gilead Sciences, INC.	8.30%	4,977,089	$136.8M
2	Ally Bridge Group (NY) LLC	3.40%	140,000	$3.8M
3	Commodore Capital LP	2.32%	1,415,000	$38.9M
4	B Group, Inc.	2.27%	175,706	$4.8M
5	Parkman Healthcare Partners LLC	2.03%	721,181	$19.8M
6	Squadron Capital Management LLC	1.36%	160,000	$4.4M
7	Dv Equities, LLC	0.89%	226,415	$6.2M
8	Stempoint Capital LP	0.81%	170,378	$4.7M
9	Paradigm Biocapital Advisors LP	0.80%	1,553,748	$42.7M
10	HighVista Strategies LLC	0.46%	73,405	$2.0M
11	Monimus Capital Management, LP	0.30%	47,580	$1.3M
12	Ra Capital Management, L.P.	0.24%	1,020,410	$28.0M
13	Affinity Asset Advisors, LLC	0.24%	190,000	$5.2M
14	Palumbo Wealth Management LLC	0.11%	19,865	$546K
15	Virtus Investment Advisers, LLC	0.09%	14,251	$392K
16	Persistent Asset Partners Ltd	0.06%	6,942	$191K
17	Integrated Quantitative Investments LLC	0.05%	10,078	$277K
18	ADAR1 Capital Management, LLC	0.03%	20,447	$562K
19	Driehaus Capital Management LLC	0.02%	150,000	$4.1M
20	Schonfeld Strategic Advisors LLC	0.02%	242,153	$6.7M
21	Eversept Partners, LP	0.02%	16,510	$454K
22	XTX Topco Ltd	0.02%	42,918	$1.2M
23	Point72 Asset Management, L.P.	0.01%	460,593	$12.7M
24	Woodline Partners LP	0.01%	150,780	$4.1M
25	Jupiter Topco LLC	0.01%	849,309	$23.4M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Assembly Biosciences Inc (ASMB)

What does the Smart Money Trend signal show for ASMB?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added ASMB than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ASMB?

More buyers than sellers — 60% buying: Last quarter: 43 funds were net buyers (14 opened a brand new position + 29 added to an existing one). Only 29 were sellers (17 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for ASMB holders?

Smaller funds dominant — 13% AUM from top-100: 22 of 71 holders rank in the top 100 by AUM, but together hold only 13% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held ASMB?

Mostly new holders — 59% entered in last year: Only 11 funds (15%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Assembly Biosciences Inc (ASMB) following the 2026 Q2 hedge fund 13F filings?

As of today, ASMB has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ASMB has gained +19.9% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Assembly Biosciences Inc (ASMB)

Smart Money Signals — ASMB

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +97% more funds vs a year ago

More buyers than sellers — 60% buying

Fewer new buyers each quarter (-7 vs last Q)

Mostly new holders — 59% entered in last year

Buying through price weakness — shares -1%, value -20%

Steady discovery — ~14 new funds/quarter

Early stage — 61% of holders entered in last year

Smaller funds dominant — 13% AUM from top-100

Institutional Sentiment Summary — ASMB

Hedge Fund Ownership: ASMB

Market Analysis: ASMB

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: ASMB

Is It Too Late to Buy Assembly Biosciences Inc (ASMB) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: ASMB

Statistics: ASMB

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Assembly Biosciences Inc (ASMB)

Welcome to 13Foresight!